Figure 2.

In vivo antitumor activities of STEAP1 bispecific antibodies. (A) In vivo antitumor effect of STEAP1 BsAb in the presence of human T cells against TC-32 cell line xenografts; 3×10⁶ cells of TC32 were subcutaneously implanted into mice, and 10 µg of STEAP1 BsAb and 2×10⁷ of T cells were administered twice per week for 2–3 weeks to treat the tumors. Tumor growth and relative body weight of mice were monitored, and overall survivals of the mice were plotted. (B) In vivo antitumor effect of BC261 against huge established TC-32 tumor xenografts. When tumors reached 2000 mm³, 10 µg of BC261 and 2×10⁷ of T cells were started. Huge EFT xenografts successfully regressed by BC261 treatment. EFT, Ewing sarcoma family of tumors; STEAP, six-transmembrane epithelial antigen of prostate.